Study on CBX-12 for Women with Ovarian Cancer Resistant to Platinum Treatments

Sponsor: Cybrexa Therapeutics

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06315491

Provider View

This clinical trial is testing the safety and effectiveness of a new drug, CBX-12, in women with ovarian cancer that has not responded to or has returned after platinum-based treatments. The study will compare two different doses of the drug.

Patient Parameters

Program Overview

The aim of this study is to evaluate how safe and effective the drug CBX-12 is for women with ovarian cancer that has not responded to or has come back after platinum-based chemotherapy. Participants will receive one of two doses of CBX-12 every 21 days to see which dose works best and is well-tolerated.

Eligibility Criteria

Inclusion Criteria

  • Women diagnosed with high-grade serous cancer of the ovary, fallopian tube, or primary peritoneum that has not responded to previous treatments.
  • Cancer must be resistant to platinum-based chemotherapy, meaning it either progressed during treatment or within 26 weeks after the last dose.
  • May have had up to two additional treatments for advanced cancer, not counting maintenance therapies.
  • Must be 18 years or older.
  • Must have measurable cancer according to specific medical criteria.
  • Must agree to participate and sign a consent form.
  • Must be in good general health, able to carry out normal activities or light work.
  • Must have adequate liver, kidney, blood, lung, and blood clotting function.

Exclusion Criteria

  • Have received chemotherapy, biological, or investigational treatments, or radiation within 3 weeks before starting the study.
  • Currently taking any other cancer treatments or investigational drugs.
  • Have any significant ongoing illnesses.
  • Have active HIV infection.
  • Have active hepatitis B or C infection.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.